Broad-spectrum anti-infective peptides

Abstract

Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.

1 . (canceled) 
     
     
         2 . A peptide of 16 to 26 amino acid residues in length comprising the following amino acid sequence:
 X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1  is S or G; X 2  is S or G; X 3  is V; X 4  is W; X 5  is W or K; and X 6  is W, K or A (SEQ ID NO:13).   
     
     
         3 . A peptide of 16 to 26 amino acid residues in length comprising the following amino acid sequence: SGSWLRDVWTWLQSKL (SEQ ID NO:1). 
     
     
         4 - 7 . (canceled) 
     
     
         8 . The peptide of  claim 3 , which consists of the following amino acid sequence: SGSWLRDVWTWLQSKL (SEQ ID NO:1). 
     
     
         9 - 10 . (canceled) 
     
     
         11 . The peptide of  claim 8 , wherein the amino acid residues are L amino acids, D amino acids, or a mixture of D and L amino acids. 
     
     
         12 - 17 . (canceled) 
     
     
         18 . A pegylated peptide comprising the peptide as defined in  claim 3  linked to one, two or more polyethylene glycol (PEG) polymers. 
     
     
         19 - 27 . (canceled) 
     
     
         28 . The pegylated peptide of  claim 18 , wherein the one, two or more PEG polymers is linked to the N-terminus of the peptide, or the C-terminus of the peptide. 
     
     
         29 - 31 . (canceled) 
     
     
         32 . The pegylated peptide of  claim 18 , which comprises the following structure: NH 2 -PEG12-Amide-PEG12-peptide. 
     
     
         33 - 47 . (canceled) 
     
     
         48 . The pegylated peptide of  claim 18 , wherein each PEG polymer is in the molecular weight range of 500 to 5000 daltons. 
     
     
         49 . The pegylated peptide of  claim 48 , wherein the one, two or more PEG polymers is branched or non-branched. 
     
     
         50 - 51 . (canceled) 
     
     
         52 . A composition comprising the peptide of  claim 3  and a carrier. 
     
     
         53 . A composition comprising the pegylated peptide of  claim 18  and a carrier. 
     
     
         54 - 59 . (canceled) 
     
     
         60 . A pharmaceutical composition comprising an effective amount of the peptide of  claim 3  and a pharmaceutically acceptable carrier. 
     
     
         61 - 79 . (canceled) 
     
     
         80 . A method for treating a microorganism infection in a human, comprising administering to the human the pharmaceutical composition of  claim 60 . 
     
     
         81 . (canceled) 
     
     
         82 . The method of  claim 80 , wherein the microorganism is a bacteria or a virus. 
     
     
         83 . The method of  claim 82 , wherein the bacteria is Gram-positive or Gram negative. 
     
     
         84 . The method of  claim 83 , wherein the Gram-positive-bacteria is  Staphylococcus aureus , enterococci, streptococci,  Clostridium difficile, Propionibacterium acnes , or  Bacillus anthracis.    
     
     
         85 . (canceled) 
     
     
         86 . The method of  claim 83 , wherein the Gram-negative bacteria is  Pseudomonas aeruginosa, Moraxella catarrhalis , or  Haemophilus influenzae.    
     
     
         87 . The method of  claim 82 , wherein the bacteria is Methicillin-sensitive  Staphylococcus aureus , Methicillin-resistant  Staphylococcus aureus , Vancomycin-sensitive enterococci, Vancomycin-resistant enterococci, penicillin-sensitive  Streptococcus pneumoniae , penicillin-resistant  Streptococcus pneumoniae , ciprofloxacin-resistant or clindamycin-resistant. 
     
     
         88 - 94 . (canceled) 
     
     
         95 . The method of  claim 82 , wherein the virus belongs to the flaviviridae, togaviridae, filoviridae, arenaviridae, poxviridae, bunyaviridae, or retroviridae family. 
     
     
         96 . The method of  claim 82 , wherein the virus is a dengue virus, Zika virus, Yellow Fever virus, Japanese encephalitis virus, Marburg virus, Chikungunya virus, Ebola virus, HIV, or influenza virus. 
     
     
         97 - 122 . (canceled)